Jump to main content
Jump to site search

Issue 4, 2019
Previous Article Next Article

Programmed supramolecular nanoassemblies: enhanced serum stability and cell specific triggered release of anti-cancer drugs

Author affiliations

Abstract

A bolaamphiphilic cross-linked nanoassembly endowed with pH responsive degradation features has been designed and fabricated for stable noncovalent guest encapsulation and controlled release. The self-assembled bolaamphiphile is utilized to prepare cross-linked nanoassemblies to further stabilize the noncovalent guest encapsulation at a concentration below its critical aggregation concentration (CAC) in a large volume of water or serum for drug delivery applications. Thus, this system can simultaneously address premature drug release and safety issues. The nanoassemblies integrated with a β-thioester linker, which can be hydrolyzed selectively under mildly acidic conditions (pH ∼ 5.3) at a slow rate, thus enable controlled release of guest molecules. Biological evaluation revealed that doxorubicin loaded cross-linked nanoassemblies (CNs–DOX) are nontoxic to normal cells such as HEK-293 or PBMC, but in contrast, showed a robust apoptotic effect on colon cancer cells, HCT-116, indicating excellent specificity. Thus, the fabrication reproducibility, robust stability, triggered drug release and cell selective toxicity behavior make this small molecular system very promising in the field of chemotherapeutic applications.

Graphical abstract: Programmed supramolecular nanoassemblies: enhanced serum stability and cell specific triggered release of anti-cancer drugs

Back to tab navigation

Supplementary files

Publication details

The article was received on 27 Jan 2019, accepted on 29 Jan 2019 and first published on 01 Feb 2019


Article type: Paper
DOI: 10.1039/C9NA00052F
Nanoscale Adv., 2019,1, 1571-1580
  • Open access: Creative Commons BY-NC license
  •   Request permissions

    Programmed supramolecular nanoassemblies: enhanced serum stability and cell specific triggered release of anti-cancer drugs

    S. Mondal, M. Saha, M. Ghosh, S. Santra, M. A. Khan, K. Das Saha and M. R. Molla, Nanoscale Adv., 2019, 1, 1571
    DOI: 10.1039/C9NA00052F

    This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Material from this article can be used in other publications provided that the correct acknowledgement is given with the reproduced material and it is not used for commercial purposes.

    Reproduced material should be attributed as follows:

    • For reproduction of material from NJC:
      [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the Centre National de la Recherche Scientifique (CNRS) and the RSC.
    • For reproduction of material from PCCP:
      [Original citation] - Published by the PCCP Owner Societies.
    • For reproduction of material from PPS:
      [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the European Society for Photobiology, the European Photochemistry Association, and RSC.
    • For reproduction of material from all other RSC journals:
      [Original citation] - Published by The Royal Society of Chemistry.

    Information about reproducing material from RSC articles with different licences is available on our Permission Requests page.

Search articles by author

Spotlight

Advertisements